RxSight (RXST) Stock Price, News & Analysis

Company Overview

RxSight, Inc. is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. The company obtained CE marking in Europe for its LAL technology and later secured U.S. Food and Drug Administration approval for its second‐generation device in October 2020. Since then, RxSight has partnered with leading ophthalmology centers to integrate the LAL system into clinical practice, building a network of implantation sites throughout North America and preparing for broader global expansion under existing regulatory frameworks.

In addition to its core LAL offering, RxSight continues to invest in research and development aimed at enhancing its lens portfolio and refining adjustment protocols. The company collaborates with ophthalmic surgeons and research institutions to advance surgical workflows and patient education initiatives. Under the leadership of President and Chief Executive Officer Steve McKnight, RxSight is committed to driving innovation in presbyopia correction and setting new standards for patient-centric eye care solutions.

Key Stats

• Today's Range: $6.25 to $6.59
• 50-Day Range: $4.59 to $6.29
• 52-Week Range: $4.48 to $13.22
• Volume: 1.15 million shs
• Average Volume: 979,300 shs
• Market Capitalization: $273.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.37
• Consensus Rating: Reduce

RxSight Stock Analysis - MarketRank™

RxSight scored higher than 77% of companies evaluated by MarketBeat, and ranked 174th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Reduce

Consensus Rating

RxSight has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on no strong buy ratings, 2 buy ratings, 7 hold ratings, and 3 sell ratings.

Upside Potential

RxSight has a consensus price target of $8.37, representing about 27.3% upside from its current price of $6.57.

Amount of Analyst Coverage

RxSight has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for RxSight are expected to grow in the coming year, from ($1.31) to ($1.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of RxSight is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of RxSight is -5.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

RxSight has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.32% of the float of RxSight has been sold short.

Short Interest Ratio / Days to Cover

RxSight has a short interest ratio ("days to cover") of 2.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RxSight has recently decreased by 30.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RxSight does not currently pay a dividend.

Dividend Growth

RxSight does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.51

News Sentiment

RxSight has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for RxSight this week, compared to 6 articles on an average week.

Search Interest

2 people have searched for RXST on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, RxSight insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.05% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:RXST
• CIK: 1111485
• Web: www.rxsight.com
• Phone: 949-521-7830
• Fax: N/A
• Employees: 220
• Year Founded: 1997

Price Target and Rating

• Average Price Target for RxSight: $8.37
• High Price Target: $11.00
• Low Price Target: $6.30
• Potential Upside/Downside: +27.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.94 million
• Net Margins: -36.80%
• Pretax Margin: -36.71%
• Return on Equity: -17.35%
• Return on Assets: -14.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.07
• Quick Ratio: 3.61

Sales & Book Value

• Annual Sales: $134.48 million
• Price / Sales: 2.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.70 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 41,590,000
• Free Float: 37,413,000
• Market Cap: $273.25 million
• Optionable: Optionable
• Beta: 1.13